
OptimizeRx Corporation: updates and filings
Price
$7.12
November 19, 2026Market cap $134M
What Ploutos Investor adds for OptimizeRx
Part of Ploutos Investor, €9.99 a month
- The full history: 16 fiscal years, from 2010
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 13, 2026next Feb 11, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
August 2026
June 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 13, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 13, 2026Results of operationsForm8-K
- Oct 21, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 20, 2026Shares registered for employeesFormS-8
- Aug 14, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 13, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 12, 2026Results of operations, officer or director change, Regulation FD disclosureForm8-K
- Jul 29, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jul 22, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jun 12, 2026Officer or director change, shareholder voteForm8-K
- Jun 5, 2026Officer or director changeForm8-K
- Jun 1, 2026Additional annual meeting materialFormDEFA14A
- May 13, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 12, 2026Material agreement entered, material agreement ended, results of operations, new material financial obligationForm8-K
- Apr 30, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 30, 2026Annual meeting proxy statementFormDEF 14A
- Apr 9, 2026Officer or director change, Regulation FD disclosureForm8-K
- Mar 30, 2026Change of auditorForm8-K
- Mar 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Mar 12, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Mar 5, 2026Material agreement entered, results of operations, other material eventsForm8-K
- Nov 7, 2025Quarterly reportfor the period to Sep 30, 2025Form10-Q
- Nov 6, 2025Results of operationsForm8-K
- Oct 31, 2025Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 19, 2025Officer or director change, Regulation FD disclosureForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 13, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 13, 2026 | 8-K | Results of operations | Document |
| Oct 21, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 20, 2026 | S-8 | Shares registered for employees | Document |
| Aug 14, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 13, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 12, 2026 | 8-K | Results of operations, officer or director change, Regulation FD disclosure | Document |
| Jul 29, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jul 22, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jun 12, 2026 | 8-K | Officer or director change, shareholder vote | Document |
| Jun 5, 2026 | 8-K | Officer or director change | Document |
| Jun 1, 2026 | DEFA14A | Additional annual meeting material | Document |
| May 13, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 12, 2026 | 8-K | Material agreement entered, material agreement ended, results of operations, new material financial obligation | Document |
| Apr 30, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 30, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 9, 2026 | 8-K | Officer or director change, Regulation FD disclosure | Document |
| Mar 30, 2026 | 8-K | Change of auditor | Document |
| Mar 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Mar 12, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Mar 5, 2026 | 8-K | Material agreement entered, results of operations, other material events | Document |
| Nov 7, 2025 | 10-Q | Quarterly reportfor the period to Sep 30, 2025 | Document |
| Nov 6, 2025 | 8-K | Results of operations | Document |
| Oct 31, 2025 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 19, 2025 | 8-K | Officer or director change, Regulation FD disclosure | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Nov 12, 2008.
The full analysis
What do OptimizeRx's filings show?
The filings are where every one of OptimizeRx's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.